Chemical Structure (Bortezomib 01)
Bortezomib Injection, Powder, Lyophilized, For Solution
Product Images NDC 68001-540
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Bortezomib (NDC 68001-540). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Bluepoint Laboratories, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1 (Bortezomib 02)
Figure 2 (Bortezomib 03)
Not-Available. The text seems to be random characters and numbers that do not form a coherent description.*
Figure 3 (Bortezomib 04)
Figure 4 (Bortezomib 05)
This text seems to be showing the results of a study involving the use of Bortezomib and Dexamethasone in patients. It includes some numeric values and a p-value from a log-rank test. However, without additional context, it is difficult to determine the purpose of the study or the significance of the results.*
Figure 5 (Bortezomib 06)
Figure 6 (Bortezomib 07)
Vial Label (Bortezomib 08)
This is the packaging information for Bortezomib, a cytotoxic injection for intravenous or subcutaneous use. It contains 3.5 mg of Bortezomib and 35 mg of mannitol. The instructions advise to discard any unused portion and store at no more than 25°C, protecting it from light. It also includes standard safety warnings and dosage instructions. The product is manufactured by Bliss Paint Laboratories in China.*
Carton Label (Bortezomib 09)
Inside Flap (Bortezomib 10)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
